These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30377936)

  • 21. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma.
    Nakaigawa N; Kondo K; Kaneta T; Tateishi U; Minamimoto R; Namura K; Ueno D; Kobayashi K; Kishida T; Ikeda I; Hasumi H; Makiyama K; Hayashi N; Osaka K; Muraoka K; Izumi K; Kawahara T; Teranishi JI; Miyoshi Y; Yumura Y; Uemura H; Inoue T; Yao M
    Cancer Chemother Pharmacol; 2018 Apr; 81(4):739-744. PubMed ID: 29464355
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Kitajima K; Fukushima K; Yamamoto S; Kato T; Odawara S; Takaki H; Kobayashi K; Yamano T; Yamakado K; Nakanishi Y; Kanematsu A; Nojima M; Suzumura K; Hatano E; Fujimoto J; Kihara T; Nakasho K; Hirota S; Hirota S
    Nagoya J Med Sci; 2017 Feb; 79(2):273-277. PubMed ID: 28626263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
    Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
    Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
    Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. F-18 FDG PET in detecting renal cell carcinoma.
    Ak I; Can C
    Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clear cell renal cell carcinoma: discrimination from other renal cell carcinoma subtypes and oncocytoma at multiphasic multidetector CT.
    Young JR; Margolis D; Sauk S; Pantuck AJ; Sayre J; Raman SS
    Radiology; 2013 May; 267(2):444-53. PubMed ID: 23382290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lesion detection by [
    Verhoeff SR; van Es SC; Boon E; van Helden E; Angus L; Elias SG; Oosting SF; Aarntzen EH; Brouwers AH; Kwee TC; Heskamp S; Hoekstra OS; Verheul H; van der Veldt AAM; de Vries EGE; Boerman OC; van der Graaf WTA; Oyen WJG; van Herpen CML
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1931-1939. PubMed ID: 31172212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal Mucinous Tubular and Spindle Cell Carcinoma Shows a High Uptake on
    Furuya S; Manabe O; Nanbu T; Yamashita N; Shinnno Y; Kasai K; Kroenke M; Tamaki N
    Intern Med; 2018 Apr; 57(8):1131-1134. PubMed ID: 29279490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
    Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
    J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of Relative Enhancement on Multiphasic MRI for the Differentiation of Clear Cell Renal Cell Carcinoma (RCC) From Papillary and Chromophobe RCC Subtypes and Oncocytoma.
    Young JR; Coy H; Kim HJ; Douek M; Lo P; Pantuck AJ; Raman SS
    AJR Am J Roentgenol; 2017 Apr; 208(4):812-819. PubMed ID: 28125273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual-tracer PET/CT in renal angiomyolipoma and subtypes of renal cell carcinoma.
    Ho CL; Chen S; Ho KM; Chan WK; Leung YL; Cheng KC; Wong KN; Cheung MK; Wong KK
    Clin Nucl Med; 2012 Nov; 37(11):1075-82. PubMed ID: 22996247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT.
    Kim JK; Park SY; Shon JH; Cho KS
    Radiology; 2004 Mar; 230(3):677-84. PubMed ID: 14990834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
    Ito H; Kondo K; Kawahara T; Kaneta T; Tateishi U; Ueno D; Namura K; Kobayashi K; Miyoshi Y; Yumura Y; Makiyama K; Hayashi N; Hasumi H; Osaka K; Yokomizo Y; Teranishi JI; Hattori Y; Inoue T; Uemura H; Yao M; Nakaigawa N
    Cancer Chemother Pharmacol; 2017 May; 79(5):855-861. PubMed ID: 28331985
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer.
    Mizuno T; Kamai T; Abe H; Sakamoto S; Kitajima K; Nishihara D; Yuki H; Kambara T; Betsunoh H; Yashi M; Fukabori Y; Kaji Y; Yoshida K
    BMC Cancer; 2015; 15():1097. PubMed ID: 25784113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance of MRI, SPECT, and PET in detecting renal cell carcinoma: a systematic review and meta-analysis.
    Yin Q; Xu H; Zhong Y; Ni J; Hu S
    BMC Cancer; 2022 Feb; 22(1):163. PubMed ID: 35148700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging of acquired cystic disease-associated renal cell carcinoma by contrast-enhanced ultrasonography with perflubutane microbubbles and positron emission tomography-computed tomography.
    Ishikawa I; Morita K; Hayama S; Nakazawa T; Araki I; Higashi K; Miyazawa K; Suzuki K; Nojima T
    Clin Exp Nephrol; 2011 Feb; 15(1):136-40. PubMed ID: 20824295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
    J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.